EGFR and gastric cancer: In pursuing this concept, we analyzed for the first time the effects of a class I-selective HDACi treatment on the possible upregulation of components of the oncogenic EGF receptor (EGFR) signalling pathway (receptor or ligands) in gastric cancer cells.